Emerging RNAi-Based Therapies for FCS, Dyslipidemia - Episode 2

Quality of Life and Diagnostic Considerations for FCS

Published on: September 23, 2024

Kausik K. Ray, MD, MRCP: From the Department of Public Health, Gerald Watts, MD, PhD

Panelists discuss how familial chylomicronemia syndrome (FCS) imposes a significant economic burden on patients, affecting their ability to stay employed and manage the costs associated with long-term care and treatment.

EP. 1: Familial Chylomicronemia Syndrome: Diagnosis, Genetic Factors, and Long-Term Health Implications

Now Viewing

EP. 2: Quality of Life and Diagnostic Considerations for FCS

EP. 3: PALISADE Study: Plozasiran’s Efficacy and Potential in Reducing Triglycerides and Pancreatitis

EP. 4: Emerging Research of RNAi-Based Therapies for FCS

EP. 5: Reflections on Plozasiran Trial Data and Future Potential

EP. 6: SHASTA-2 Trial: Plozasiran’s Efficacy in Reducing Triglycerides and APOC3

Video content above is prompted by the following:

What economic burden does familial chylomicronemia syndrome have on patients?